Takayuki Yamamoto1, Antonino Spinelli2, Yasuo Suzuki3, Rogerio Saad-Hossne4, Fabio Vieira Teixeira5, Idblan Carvalho de Albuquerque6, Rodolff Nunes da Silva7, Ivan Folchini de Barcelos7, Ken Takeuchi3, Akihiro Yamada3, Takahiro Shimoyama1, Lorete Maria da Silva Kotze8, Matteo Sacchi9, Silvio Danese10, Paulo Gustavo Kotze7. 1. IBD Centre, Yokkaichi Hazu Medical Centre, Yokkaichi, Japan. 2. Colorectal Surgery Unit, Humanitas Research Hospital, Department of Medical Biotechnologies and Translational Medicine, University of Milan, Milan, Italy. 3. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Toho University Medical Centre, Sakura Hospital, Faculty of Medicine, Toho University, Sakura, Japan. 4. Digestive Surgery Department, São Paulo State University (UNESP), Botucatu, Brazil. 5. Colorectal Surgery, Gastrosaude, Marilia, Brazil. 6. IBD Unit, Heliopolis Hospital, São Paulo, Brazil. 7. Colorectal Surgery Unit, Catholic University of Parana, Curitiba, Brazil. 8. Gastroenterology Unit, Catholic University of Parana, Curitiba, Brazil. 9. Colorectal Surgery Unit, Humanitas Research Hospital, Milan, Italy. 10. IBD Unit, Humanitas Research Hospital, Milano, Italy.
Abstract
BACKGROUND: Author note: TY, AS, YS, FVT and PGK designed the study. All authors did data collection and gave scientific contribution to the study design and discussion. TY, AS and PGK drafted the article. All authors read and approved the final version of the manuscript.In the era of biologic agents, risk factors for complications following resection for Crohn's disease have not been fully identified. In particular, the association of preoperative use of immunosuppressive and biologic agents with the incidence of complications after resection remains to be elucidated. AIM: This retrospective multicentre study aimed to identify risk factors for complications after ileocolonic resection for Crohn's disease, with a major focus on the impact of preoperative immunosuppressive and biologic therapy. METHODS: A total of 231 consecutive patients who underwent ileocolonic resections for active Crohn's disease in seven inflammatory bowel disease referral centres from three countries (Japan, Brazil and Italy) were included. The following variables were investigated as potential risk factors: age at surgery, gender, behaviour of Crohn's disease (perforating vs. non-perforating disease), smoking, preoperative use (within eight weeks before surgery) of steroids, immunosuppressants and biologic agents, previous resection, blood transfusion, surgical procedure (open vs. laparoscopic approach), and type of anastomosis (side-to-side vs. end-to-end). Postoperative complications occurring within 30 days after surgery were recorded. RESULTS: The rates of overall complications, intra-abdominal sepsis, and anastomotic leak were 24%, 12% and 8%, respectively. Neither immunosuppressive nor biologic therapy prior to surgery was significantly associated with the incidence of overall complications, intra-abdominal sepsis or anastomotic leak. In multivariate analysis, blood transfusion, perforating disease and previous resection were significant risk factors for overall complications (odds ratio [OR] 3.02, 95% confidence interval [CI] 1.21-7.52; P = 0.02), intra-abdominal sepsis (OR 2.67, 95% CI 1.04-6.86; P = 0.04) and anastomotic leak (OR 2.87, 95% CI 1.01-8.18; P = 0.048), respectively. CONCLUSIONS: Blood transfusion, perforating disease and previous resection were significant risk factors for overall complications, intra-abdominal sepsis and anastomotic leak after ileocolonic resection for Crohn's disease, respectively. Preoperative immunosuppressive or biologic therapy did not increase the risk of postoperative complications.
BACKGROUND: Author note: TY, AS, YS, FVT and PGK designed the study. All authors did data collection and gave scientific contribution to the study design and discussion. TY, AS and PGK drafted the article. All authors read and approved the final version of the manuscript.In the era of biologic agents, risk factors for complications following resection for Crohn's disease have not been fully identified. In particular, the association of preoperative use of immunosuppressive and biologic agents with the incidence of complications after resection remains to be elucidated. AIM: This retrospective multicentre study aimed to identify risk factors for complications after ileocolonic resection for Crohn's disease, with a major focus on the impact of preoperative immunosuppressive and biologic therapy. METHODS: A total of 231 consecutive patients who underwent ileocolonic resections for active Crohn's disease in seven inflammatory bowel disease referral centres from three countries (Japan, Brazil and Italy) were included. The following variables were investigated as potential risk factors: age at surgery, gender, behaviour of Crohn's disease (perforating vs. non-perforating disease), smoking, preoperative use (within eight weeks before surgery) of steroids, immunosuppressants and biologic agents, previous resection, blood transfusion, surgical procedure (open vs. laparoscopic approach), and type of anastomosis (side-to-side vs. end-to-end). Postoperative complications occurring within 30 days after surgery were recorded. RESULTS: The rates of overall complications, intra-abdominal sepsis, and anastomotic leak were 24%, 12% and 8%, respectively. Neither immunosuppressive nor biologic therapy prior to surgery was significantly associated with the incidence of overall complications, intra-abdominal sepsis or anastomotic leak. In multivariate analysis, blood transfusion, perforating disease and previous resection were significant risk factors for overall complications (odds ratio [OR] 3.02, 95% confidence interval [CI] 1.21-7.52; P = 0.02), intra-abdominal sepsis (OR 2.67, 95% CI 1.04-6.86; P = 0.04) and anastomotic leak (OR 2.87, 95% CI 1.01-8.18; P = 0.048), respectively. CONCLUSIONS: Blood transfusion, perforating disease and previous resection were significant risk factors for overall complications, intra-abdominal sepsis and anastomotic leak after ileocolonic resection for Crohn's disease, respectively. Preoperative immunosuppressive or biologic therapy did not increase the risk of postoperative complications.
Authors: L Marchal; G D'Haens; G Van Assche; S Vermeire; M Noman; M Ferrante; M Hiele; M Bueno De Mesquita; A D'Hoore; F Penninckx; P Rutgeerts Journal: Aliment Pharmacol Ther Date: 2004-04-01 Impact factor: 8.171
Authors: Jean-Frédéric Colombel; William J Sandborn; Paul Rutgeerts; Robert Enns; Stephen B Hanauer; Remo Panaccione; Stefan Schreiber; Dan Byczkowski; Ju Li; Jeffrey D Kent; Paul F Pollack Journal: Gastroenterology Date: 2006-11-29 Impact factor: 22.682
Authors: Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts Journal: Lancet Date: 2002-05-04 Impact factor: 79.321
Authors: Mukta K Krane; Marco E Allaix; Marco Zoccali; Konstantin Umanskiy; Michele A Rubin; Anthony Villa; Roger D Hurst; Alessandro Fichera Journal: Dis Colon Rectum Date: 2013-04 Impact factor: 4.585
Authors: Christian Galata; Christel Weiss; Julia Hardt; Steffen Seyfried; Stefan Post; Peter Kienle; Karoline Horisberger Journal: Int J Colorectal Dis Date: 2018-05-07 Impact factor: 2.571
Authors: Christian Galata; Peter Kienle; Christel Weiss; Steffen Seyfried; Christoph Reißfelder; Julia Hardt Journal: Int J Colorectal Dis Date: 2018-11-20 Impact factor: 2.571
Authors: J Wagner; V Luber; J F Lock; U A Dietz; S Lichthardt; N Matthes; K Krajinovic; C-T Germer; S Knop; A Wiegering Journal: Chirurg Date: 2018-02 Impact factor: 0.955